NeuroMetrix Reports Q1 2024 Business Highlights
15 mai 2024 16h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. today reported financial and business highlights for the quarter ended March 31, 2024.
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
19 avr. 2024 08h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders.
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
14 mars 2024 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck...
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
13 mars 2024 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
22 févr. 2024 07h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. today reported financial and business highlights for the quarter and full year ended December 31, 2023.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
15 févr. 2024 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
13 févr. 2024 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain...
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
08 janv. 2024 09h43 HE
|
NeuroMetrix, Inc.
NeuroMetrix announced today that the Company’s Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024.
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
12 déc. 2023 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with Long COVID.
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
05 déc. 2023 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.